PROFILBARU.COM

Anaprazole
Identifiers
	IUPAC name 2-[[3-(3-methoxypropoxy)-2-methylphenyl]methylsulfinyl]-6,7-dihydro-1H-furo[2,3-f]benzimidazole;
PubChem CID	156009457;
ChemSpider	128732661; Na+ salt: 128433794;
UNII	W6OO9ZB0FC;
ChEMBL	ChEMBL4651083; Na+ salt: ChEMBL4650347;
Chemical and physical data
Formula	C21H24N2O4S
Molar mass	400.49 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES CC1=C(C=CC=C1OCCCOC)CS(=O)C2=NC3=C(N2)C=C4CCOC4=C3;
	InChI InChI=InChI=1S/C21H24N2O4S/c1-14-16(5-3-6-19(14)26-9-4-8-25-2)13-28(24)21-22-17-11-15-7-10-27-20(15)12-18(17)23-21/h3,5-6,11-12H,4,7-10,13H2,1-2H3,(H,22,23); Key:JYSIFLQJDVIWKM-UHFFFAOYSA-N;

Anaprazole is a pharmaceutical drug used for the treatment of duodenal ulcers. It is classified as a proton pump inhibitor (PPI).^[1] It was approved for use in China in 2023.^[2] It is formulated as its sodium salt, anaprazole sodium, in enteric-coated tablets.^[2]

References

^ Wang F, Niu X, Liu F, Ma X, Cheng F, Xu H, et al. (July 2024). "Safety, Tolerability, and Pharmacokinetics of Anaprazole, a Novel Proton Pump Inhibitor, in Healthy Chinese Subjects". Clinical Pharmacology in Drug Development. 13 (7): 782–789. doi:10.1002/cpdd.1405. PMID 38629191.
^ ^a ^b "Anaprazole Sodium Enteric-coated Tablets Approved for Marketing by China NMPA". Chinese National Medical Products Administration. 2023-06-25.

This drug article relating to the gastrointestinal system is a stub. You can help Wikipedia by expanding it.

[1] Wang F, Niu X, Liu F, Ma X, Cheng F, Xu H, et al. (July 2024). "Safety, Tolerability, and Pharmacokinetics of Anaprazole, a Novel Proton Pump Inhibitor, in Healthy Chinese Subjects". Clinical Pharmacology in Drug Development. 13 (7): 782–789. doi:10.1002/cpdd.1405. PMID 38629191.

[NMPA-2] "Anaprazole Sodium Enteric-coated Tablets Approved for Marketing by China NMPA". Chinese National Medical Products Administration. 2023-06-25.

[1]

[2]